Lyophilized BPI viper antivenom(University of Oxford)(Lyophilized BPI viper antivenom(University of Oxford))

概要

基本信息

药物类型

抗毒素

别名-

靶点-

作用方式-

作用机制-

治疗领域

血液及淋巴系统疾病其他疾病

在研适应症-

非在研适应症

凝血障碍蛇咬伤

原研机构

University of Oxford

在研机构-

非在研机构

University of Oxford

权益机构-

最高研发阶段暂停临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Lyophilized BPI viper antivenom(University of Oxford) 相关的临床试验

NCT04210141

/ Suspended临床2期IIT

An Adaptive Clinical Trial to Determine the Optimal Initial Dose of Lyophilized, Species Specific Monovalent Antivenom for the Management of Systemic Envenoming by Daboia Siamensis (Eastern Russell's Viper) in Myanmar

The aim of the study is to identify an 'optimal' initial dosing of the new Burma Pharmaceutical Industry (BPI) lyophilized mono-specific antivenom for patients with systemic Daboia siamensis envenoming. The initial dosing will aim to reverse venom-induced coagulopathy (as demonstrated by a negative 20 minutes Whole Blood Clotting Time (20WBCT) at 6 hours in 95% of patients whilst causing less than 5% anaphylactic reaction.

开始日期2025-04-01

申办/合作机构

University of Oxford

100 项与 Lyophilized BPI viper antivenom(University of Oxford) 相关的临床结果

登录后查看更多信息

100 项与 Lyophilized BPI viper antivenom(University of Oxford) 相关的转化医学

登录后查看更多信息

100 项与 Lyophilized BPI viper antivenom(University of Oxford) 相关的专利（医药）

登录后查看更多信息

100 项与 Lyophilized BPI viper antivenom(University of Oxford) 相关的药物交易

登录后查看更多信息